These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11902063)

  • 1. NKF takes the next step in K/DOQI process with guidelines for CKD.
    Nephrol News Issues; 2002 Mar; 16(4):52-3. PubMed ID: 11902063
    [No Abstract]   [Full Text] [Related]  

  • 2. CAN the new K/DOQI guidelines make a difference for the CKD patient.
    Fester S
    Nephrol News Issues; 2002 Apr; 16(5):27, 29. PubMed ID: 11962147
    [No Abstract]   [Full Text] [Related]  

  • 3. K/DOQI guidelines released on bone metabolism and disease in CKD.
    Massry S
    Nephrol News Issues; 2003 Nov; 17(12):38-41, 44. PubMed ID: 14640009
    [No Abstract]   [Full Text] [Related]  

  • 4. K/DOQI gets to the heart of managing dyslipidemias in patients with CKD.
    Benner D
    Nephrol Nurs J; 2005; 32(3):337-8. PubMed ID: 16035475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The new KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and CKD.
    Nelson RG; Tuttle KR
    Blood Purif; 2007; 25(1):112-4. PubMed ID: 17170547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NKF releases new KDOQI guidelines for diabetes and CKD.
    Nelson RG; Tuttle KR
    Nephrol News Issues; 2006 Jul; 20(8):29. PubMed ID: 16859230
    [No Abstract]   [Full Text] [Related]  

  • 7. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.
    Arenas MD; Alvarez-Ude F; Gil MT; Soriano A; Egea JJ; Millán I; Amoedo ML; Muray S; Carretón MA
    Nephrol Dial Transplant; 2006 Jun; 21(6):1663-8. PubMed ID: 16464885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients.
    Monge M; Shahapuni I; Oprisiu R; El Esper N; Morinière P; Massy Z; Choukroun G; Fournier A
    Nat Clin Pract Nephrol; 2006 Jun; 2(6):326-36. PubMed ID: 16932454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Appraisal of evidence and control of bias in the kidney disease outcomes quality initiative guideline development process.
    Van Wyck D; Eckardt KU; Uhlig K; Rocco M; Levin A
    Clin J Am Soc Nephrol; 2007 Jan; 2(1):8-10. PubMed ID: 17699378
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of nephrology nurses and technicians in the implementation of NKF-DOQI.
    Bender K; Swartz MD
    Nephrol News Issues; 1999 Apr; 13(4):21-3. PubMed ID: 10418445
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevention of progression of kidney disease - CARI guidelines.
    Johnson DW
    Aust Fam Physician; 2007 May; 36(5):353. PubMed ID: 17492072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Executing change in the management of chronic kidney disease: perspectives on guidelines and practice.
    Levin A; Stevens LA
    Med Clin North Am; 2005 May; 89(3):701-9. PubMed ID: 15755474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to K/DOQI practice guidelines for bone metabolism and disease.
    Hoy T; Fisher M; Barber B; Borker R; Stolshek B; Goodman W
    Am J Manag Care; 2007 Nov; 13(11):620-5. PubMed ID: 17988187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KDIGO takes clinical practice guidelines to a global level.
    Neumann ME
    Nephrol News Issues; 2006 Nov; 20(12):40-1, 43, 47. PubMed ID: 17125095
    [No Abstract]   [Full Text] [Related]  

  • 15. Changes noted to KDOQI guidelines for vascular access.
    Besarab A; Dinwiddie L
    Nephrol News Issues; 2006 Aug; 20(9):36. PubMed ID: 16916058
    [No Abstract]   [Full Text] [Related]  

  • 16. Chronic kidney disease and cardiovascular disease--using the ANNA Standards and Practice Guidelines to improve care. Part 1: the epidemiology of chronic kidney disease: the risk factors and complications that contribute to cardiovascular disease.
    McCarley PB; Burrows-Hudson S
    Nephrol Nurs J; 2006; 33(6):666-74; quiz 675-6. PubMed ID: 17219728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anaemia and mineral bone disorder in chronic kidney disease: a review of the current literature and implications for clinical nursing practice.
    Limrick C; McNichols-Thomas C
    J Ren Care; 2009 Mar; 35 Suppl 1():94-100. PubMed ID: 19222739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should we limit the ferritin upper threshold to 500 ng/ml in CKD patients?
    Dukkipati R; Kalantar-Zadeh K
    Nephrol News Issues; 2007 Jan; 21(1):34-8. PubMed ID: 17269263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hypertension, dyslipidemia and cardiovascular risk in chronic renal disease].
    Ravera M; Paoletti E
    Ital Heart J Suppl; 2004 Jun; 5(6):436-44. PubMed ID: 15471148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of standardization of creatinine in the implementation of guidelines and recommendations for CKD: implications for CKD management programmes.
    Van Biesen W; Vanholder R; Veys N; Verbeke F; Delanghe J; De Bacquer D; Lameire N
    Nephrol Dial Transplant; 2006 Jan; 21(1):77-83. PubMed ID: 16221704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.